Literature DB >> 24942865

Transcriptional and posttranslational regulation of insulin-like growth factor binding protein-3 by Akt3.

Quanri Jin1, Hyo-Jong Lee2, Hye-Young Min3, John Kendal Smith1, Su Jung Hwang2, Young Mi Whang1, Woo-Young Kim4, Yeul Hong Kim5, Ho-Young Lee6.   

Abstract

Insulin-like growth factor (IGF)-dependent and -independent antitumor activities of insulin-like growth factor binding protein-3 (IGFBP-3) have been proposed in human non-small cell lung cancer (NSCLC) cells. However, the mechanism underlying regulation of IGFBP-3 expression in NSCLC cells is not well understood. In this study, we show that activation of Akt, especially Akt3, plays a major role in the mRNA expression and protein stability of IGFBP-3 and thus antitumor activities of IGFBP-3 in NSCLC cells. When Akt was activated by genomic or pharmacologic approaches, IGFBP-3 transcription and protein stability were decreased. Conversely, suppression of Akt increased IGFBP-3 mRNA levels and protein stability in NSCLC cell lines. Characterization of the effects of constitutively active form of each Akt subtype (HA-Akt-DD) on IGFBP-3 expression in NSCLC cells and a xenograft model indicated that Akt3 plays a major role in the Akt-mediated regulation of IGFBP-3 expression and thus suppression of Akt effectively enhances the antitumor activities of IGFBP-3 in NSCLC cells with Akt3 overactivation. Collectively, these data suggest a novel function of Akt3 as a negative regulator of IGFBP-3, indicating the possible benefit of a combined inhibition of IGFBP-3 and Akt3 for the treatment of patients with NSCLC.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24942865      PMCID: PMC4178467          DOI: 10.1093/carcin/bgu129

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  55 in total

Review 1.  The emerging complexity of protein ubiquitination.

Authors:  David Komander
Journal:  Biochem Soc Trans       Date:  2009-10       Impact factor: 5.407

Review 2.  Matrix metalloproteinase proteomics: substrates, targets, and therapy.

Authors:  Charlotte J Morrison; Georgina S Butler; David Rodríguez; Christopher M Overall
Journal:  Curr Opin Cell Biol       Date:  2009-07-16       Impact factor: 8.382

3.  The effects of insulin-like growth factor binding protein-3 (IGFBP-3) on T47D breast cancer cells enriched for IGFBP-3 binding sites.

Authors:  Suresh Mishra; Liam J Murphy
Journal:  Mol Cell Biochem       Date:  2004-12       Impact factor: 3.396

4.  IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.

Authors:  I Ibanez de Caceres; M Cortes-Sempere; C Moratilla; R Machado-Pinilla; V Rodriguez-Fanjul; C Manguán-García; P Cejas; F López-Ríos; L Paz-Ares; J de CastroCarpeño; M Nistal; C Belda-Iniesta; R Perona
Journal:  Oncogene       Date:  2009-12-21       Impact factor: 9.867

5.  Mechanism of activation of protein kinase B by insulin and IGF-1.

Authors:  D R Alessi; M Andjelkovic; B Caudwell; P Cron; N Morrice; P Cohen; B A Hemmings
Journal:  EMBO J       Date:  1996-12-02       Impact factor: 11.598

6.  Inflammation-related neutrophil proteases, cathepsin G and elastase, function as insulin-like growth factor binding protein proteases.

Authors:  T L Gibson; P Cohen
Journal:  Growth Horm IGF Res       Date:  1999-08       Impact factor: 2.372

7.  Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.

Authors:  Floriana Morgillo; Woo-Young Kim; Edward S Kim; Fortunato Ciardiello; Waun Ki Hong; Ho-Young Lee
Journal:  Clin Cancer Res       Date:  2007-05-01       Impact factor: 12.531

8.  AKT regulates BRCA1 stability in response to hormone signaling.

Authors:  Andrew C Nelson; Traci R Lyons; Christian D Young; Kirk C Hansen; Steven M Anderson; Jeffrey T Holt
Journal:  Mol Cell Endocrinol       Date:  2010-01-18       Impact factor: 4.102

9.  Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells.

Authors:  L J Schedlich; T F Young; S M Firth; R C Baxter
Journal:  J Biol Chem       Date:  1998-07-17       Impact factor: 5.157

10.  Insulin-like growth factor binding proteins increase intracellular calcium levels in two different cell lines.

Authors:  Danielle Seurin; Alain Lombet; Sylvie Babajko; François Godeau; Jean-Marc Ricort
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

View more
  6 in total

1.  Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression.

Authors:  Kristen M Turner; Youting Sun; Ping Ji; Kirsi J Granberg; Brady Bernard; Limei Hu; David E Cogdell; Xinhui Zhou; Olli Yli-Harja; Matti Nykter; Ilya Shmulevich; W K Alfred Yung; Gregory N Fuller; Wei Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-03       Impact factor: 11.205

2.  Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer.

Authors:  Hye-Young Min; Hye Jeong Yun; Ji-Sun Lee; Hyo-Jong Lee; Jaebeom Cho; Hyun-Ji Jang; Shin-Hyung Park; Diane Liu; Seung-Hyun Oh; J Jack Lee; Ignacio I Wistuba; Ho-Young Lee
Journal:  Mol Cancer       Date:  2015-06-04       Impact factor: 27.401

3.  Essential role of insulin-like growth factor 2 in resistance to histone deacetylase inhibitors.

Authors:  S-C Lee; H-Y Min; H J Jung; K H Park; S Y Hyun; J Cho; J K Woo; S J Kwon; H-J Lee; F M Johnson; H-Y Lee
Journal:  Oncogene       Date:  2016-04-18       Impact factor: 9.867

Review 4.  Associations among Metabolism, Circadian Rhythm and Age-Associated Diseases.

Authors:  Yiwei Cao; Rui-Hong Wang
Journal:  Aging Dis       Date:  2017-05-02       Impact factor: 6.745

5.  Smoking-associated lung cancer prevention by blockade of the beta-adrenergic receptor-mediated insulin-like growth factor receptor activation.

Authors:  Hye-Young Min; Hye-Jin Boo; Ho Jin Lee; Hyun-Ji Jang; Hye Jeong Yun; Su Jung Hwang; John Kendal Smith; Hyo-Jong Lee; Ho-Young Lee
Journal:  Oncotarget       Date:  2016-10-25

6.  Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage.

Authors:  Shu-Hsuan Claire Hsu; Puviindran Nadesan; Vijitha Puviindran; William B Stallcup; David G Kirsch; Benjamin A Alman
Journal:  J Biol Chem       Date:  2017-12-01       Impact factor: 5.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.